Trial Profile
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic Characteristics of HM61713 Tablet in Healthy Korean, Japanese and Caucasian
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2020
Price :
$35
*
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
- 23 Nov 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Jul 2013 New trial record